Vaxart, Inc. 50,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • June 14th, 2024 • Vaxart, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 14th, 2024 Company Industry JurisdictionVaxart, Inc., Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 50,000,000 shares of common stock (the “Shares”), par value $0.0001 per share, of the Company (the “Common Stock”). The amount and form of the Shares to be purchased by the Underwriters is set forth opposite its name on Schedule A hereto
13,000,000 Shares of Common Stock CYPRESS SHARPRIDGE INVESTMENTS, INC. UNDERWRITING AGREEMENT September 21, 2010Underwriting Agreement • September 21st, 2010 • Cypress Sharpridge Investments, Inc. • Real estate investment trusts • New York
Contract Type FiledSeptember 21st, 2010 Company Industry JurisdictionCypress Sharpridge Investments, Inc., a corporation organized and existing under the laws of Maryland (the “Company”), which is externally managed and advised by Cypress Sharpridge Advisors LLC, a limited liability company organized and existing under the laws of Delaware (the “Manager”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 13,000,000 shares (the “Firm Shares”) of its Common Stock, par value $0.01 per share (the “Common Stock”). At the option of the Underwriters, the Company also proposes to issue and sell to the Underwriters up to an additional 1,950,000 shares of Common Stock (the “Additional Shares” and together with the Firm Shares, the “Shares”). Barclays Capital Inc., Credit Suisse Securities (USA) LLC and Deutsche Bank Securities Inc. are acting as the book-running managers in connection with the offering and sale of the Shares contemplated herei
9,500,000 Shares of Common Stock CYPRESS SHARPRIDGE INVESTMENTS, INC. UNDERWRITING AGREEMENT June 24, 2010Underwriting Agreement • June 25th, 2010 • Cypress Sharpridge Investments, Inc. • Real estate investment trusts • New York
Contract Type FiledJune 25th, 2010 Company Industry JurisdictionCypress Sharpridge Investments, Inc., a corporation organized and existing under the laws of Maryland (the “Company”), which is externally managed and advised by Cypress Sharpridge Advisors LLC, a limited liability company organized and existing under the laws of Delaware (the “Manager”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 9,500,000 shares (the “Firm Shares”) of its Common Stock, par value $0.01 per share (the “Common Stock”). At the option of the Underwriters, the Company also proposes to issue and sell to the Underwriters up to an additional 1,425,000 shares of Common Stock (the “Additional Shares” and together with the Firm Shares, the “Shares”). Barclays Capital Inc. is acting as the sole book-running manager in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
] Shares of Common Stock ASCENT SOLAR TECHNOLOGIES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • April 29th, 2008 • Ascent Solar Technologies, Inc. • Semiconductors & related devices • New York
Contract Type FiledApril 29th, 2008 Company Industry Jurisdiction
] Shares of Common Stock ASCENT SOLAR TECHNOLOGIES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • March 14th, 2008 • Ascent Solar Technologies, Inc. • Semiconductors & related devices • New York
Contract Type FiledMarch 14th, 2008 Company Industry Jurisdiction
8,000,000 Shares of Common Stock Capstead Mortgage Corporation UNDERWRITING AGREEMENT November 15, 2007Underwriting Agreement • November 21st, 2007 • Capstead Mortgage Corp • Real estate investment trusts • New York
Contract Type FiledNovember 21st, 2007 Company Industry JurisdictionCapstead Mortgage Corporation, a corporation organized and existing under the laws of Maryland (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 8,000,000 shares (the “Firm Shares”) of its Common Stock, par value $0.01 per share (the “Common Stock”), and, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 1,200,000 shares (the “Additional Shares”) of Common Stock. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares”. Bear, Stearns & Co. Inc. (“Bear Stearns”), JMP Securities LLC and Keefe Bruyette & Woods, Inc. are acting as lead managers in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
10,000,000 Shares of Common Stock Capstead Mortgage Corporation UNDERWRITING AGREEMENT September 26, 2007Underwriting Agreement • October 2nd, 2007 • Capstead Mortgage Corp • Real estate investment trusts • New York
Contract Type FiledOctober 2nd, 2007 Company Industry JurisdictionBEAR, STEARNS & CO. INC. JMP SECURITIES LLC KEEFE BRUYETTE & WOODS, INC. As Representatives of the several Underwriters named in Schedule I attached hereto (the “Representatives”)
300,000,000 Shares of 8.25% Series D Cumulative Redeemable Preferred Stock ANTHRACITE CAPITAL, INC. UNDERWRITING AGREEMENT February 7, 2007Underwriting Agreement • February 13th, 2007 • Anthracite Capital Inc • Real estate investment trusts • New York
Contract Type FiledFebruary 13th, 2007 Company Industry JurisdictionAnthracite Capital, Inc., a corporation organized and existing under the laws of Maryland (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 300,000,000 shares (the “Firm Shares”) of its 8.25% Series D Cumulative Redeemable Preferred Stock, par value $.001 per share, liquidation preference $25.00 per share (the “Series D Preferred Stock”), and, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 450,000 shares (the “Additional Shares”) of Series D Preferred Stock. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Bear, Stearns & Co. Inc. (“Bear Stearns”) is acting as Representative in connection with the offering and sale of the Shares contemplated herein (the “O